Twist Bioscience Corporation Announces Share Issuance in Stock Purchase Agreements

Details

Of these shares, up to 324,558 shares will be issued to Invenra Inc. in exchange for a $5 million cash payment for a license agreement and technology transfer. Additionally, up to 307,770 shares will be issued to two investors of Invenra in exchange for Invenra preferred stock, giving Twist the right to designate one director to the Invenra board. Twist is concurrently filing a prospectus supplement to register the resale of these shares under the Registration Rights Agreements entered into with the investors.

Items reported

About Twist Bioscience Corporation

Twist Bioscience Corporation is a pioneering biotechnology firm revolutionizing the field of synthetic DNA. The company's primary function is to produce synthetic DNA using a proprietary silicon-based manufacturing platform, enabling the creation of high-quality, accurate, and cost-effective DNA at scale. Twist Bioscience's innovations impact multiple sectors, including pharmaceuticals, industrial chemicals, agriculture, and data storage, offering transformative solutions in drug development, crop protection, and genomic research. By leveraging its proprietary DNA synthesis platform, Twist Bioscience plays a vital role in the broader biotechnology market, facilitating advancements that drive progress in personalized medicine and sustainable practices. With its cutting-edge technology, the company provides researchers and businesses with access to a wide array of DNA products and solutions essential for scientific discovery and technological innovation, underpinning its significance in the expanding biotech landscape.